Mostrar el registro sencillo del ítem
dc.contributor.author | Drosten, Matthias | |
dc.contributor.author | Barbacid, Mariano | |
dc.date.accessioned | 2022-07-13T09:12:47Z | |
dc.date.available | 2022-07-13T09:12:47Z | |
dc.date.issued | 2022-05-16 | |
dc.identifier.citation | Mol Oncol. 2022;16(5):1057-1071. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/14702 | |
dc.description.abstract | For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies based on personalized medicine owing to the complexity of designing inhibitors to selectively target KRAS and downstream targets with acceptable toxicities. The recent development of selective KRASG12C inhibitors represents a landmark after 40 years of intense research efforts since the identification of KRAS as a human oncogene. Here, we discuss the mechanisms responsible for the rapid development of resistance to these inhibitors, as well as potential strategies to overcome this limitation. Other therapeutic strategies aimed at inhibiting KRAS oncogenic signaling by targeting either upstream activators or downstream effectors are also reviewed. Finally, we discuss the effect of targeting the mitogen-activated protein kinase (MAPK) pathway, both based on the failure of MEK and ERK inhibitors in clinical trials, as well as on the recent identification of RAF1 as a potential target due to its MAPK-independent activity. These new developments, taken together, are likely to open new avenues to effectively treat KRAS mutant LUAD. | es_ES |
dc.description.sponsorship | This work was supported by grants from the European Research Council (ERC-2015-AdG/695566, THERACAN), the Spanish Ministry of Science, Innovation and Universities (RTC-2017-6576, RTI2018-094664-BI00) the Autonomous Community of Madrid (B2017/BMD-3884 iLUNG-CM) and the CRIS Cancer Foundation (to MB) as well as the Spanish Ministry of Science and Innovation (PID2020-116705RB-100) (to MD). MB is a recipient of an Endowed Chair from the AXA Research Fund. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject | genetically engineered mouse tumor models | es_ES |
dc.subject | KRAS(G12C) inhibitors | es_ES |
dc.subject | lung adenocarcinoma | es_ES |
dc.subject | RAF1 | es_ES |
dc.subject | RAS signaling | es_ES |
dc.subject | tumor resistance | es_ES |
dc.subject.mesh | Adenocarcinoma of Lung | es_ES |
dc.subject.mesh | Lung Neoplasms | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Mutation | es_ES |
dc.subject.mesh | Oncogenes | es_ES |
dc.subject.mesh | Protein Kinase Inhibitors | es_ES |
dc.subject.mesh | Proto-Oncogene Proteins p21(ras) | es_ES |
dc.title | Targeting KRAS mutant lung cancer: light at the end of the tunnel. | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 34951114 | es_ES |
dc.format.volume | 16 | es_ES |
dc.format.number | 5 | es_ES |
dc.format.page | 1057-1071 | es_ES |
dc.identifier.doi | 10.1002/1878-0261.13168 | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea. European Research Council (ERC) | es_ES |
dc.contributor.funder | Government of Spain | es_ES |
dc.contributor.funder | Unión Europea. Comisión Europea | es_ES |
dc.contributor.funder | Comunidad de Madrid (España) | es_ES |
dc.contributor.funder | CRIS contra el Cáncer | es_ES |
dc.contributor.funder | Fundación AXA | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1878-0261 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1002/1878-0261.13168 | es_ES |
dc.identifier.journal | Molecular oncology | es_ES |
dc.repisalud.institucion | CNIO | es_ES |
dc.repisalud.orgCNIO | CNIO::Grupos de investigación::Grupo de Oncología Experimental | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/695566/EU | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/RTC-2017-6576 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/RTI2018-094664-BI00 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/B2017/BMD-3884 iLUNG-CM | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/PID2020-116705RB-100 | es_ES |